Low scores were also found to correlate with cognitive decline and researchers hope the findings could reveal a potential new way to detect diseases like Alzheimer’s.
The researchers from King’s, together with teams from Sweden, Denmark and the US, studied a molecule called RNA. RNA is a molecular ‘
The team started by studying RNA in muscle tissue from 15 people aged 19–28 years and 15 healthy people aged between 59 and 77. They used specialist ‘chips’ to study the amount of RNA — and therefore the gene expression — in the muscle tissue and identified 150 genes that differed between people in the two age groups. They then repeated these findings using other sets of muscle samples.
The same
When the researchers used the same profile to study brain tissue they found the ‘healthy ageing’ genes could also categorize in the samples of donated brain tissue from younger and older people. The team then studied the ‘healthy ageing’ profile in RNA from blood and brain tissue and found the highest scores in healthy older people, with lower scores in people with early cognitive decline and Alzheimer’s disease.
Dr Eric Karran of Alzheimer’s Research UK, the UK’s leading dementia research charity, said:
«Advances in genetic technologies over the past decades are now allowing scientists to profile the complexities of the human body in more detail than ever before. One of the biggest questions in human biology is how we age, and how this process impacts our wider health and risk for conditions like Alzheimer’s. This study suggests a way to measure a person’s ‘biological age’ and could reveal insights into the ageing process and why some people are more susceptible to
«There is much interest in developing a blood test for diseases like Alzheimer’s but such a test would need rigorously validating to show it was accurate and sensitive before it could be used in the clinic. Furthermore, tests that confirm actual pathological changes in the brain will continue to be used for confirming or ruling out clinical diagnoses. This study will need to be repeated and validated in a larger group of people to know whether it could be a useful clinical test for Alzheimer’s or how it could improve current research practices. With an increasingly ageing population in the UK and around the world, it’s important to invest in research in this area to help understand and improve health today and for future generations.»